NASDAQ: ANIX - Anixa Biosciences, Inc.

Yield per half year: +12.78%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Anixa Biosciences, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

more details
Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1987-01-01
ISIN US03528H1095
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.anixa.com
Цена ао 3.13
Change price per day: -0.3891% (2.57)
Change price per week: -4.83% (2.69)
Change price per month: -22.66% (3.31)
Change price per 3 month: -19.75% (3.19)
Change price per half year: +12.78% (2.27)
Change price per year: -34.02% (3.88)
Change price per 3 year: -16.61% (3.07)
Change price per 5 year: -29.57% (3.635)
Change price per 10 year: 0% (2.56)
Change price per year to date: -25.58% (3.44)
All parameters

Underestimation

Title Value Grade
P/S 470.6 1
P/BV 4.23 4
P/E 0 0
EV/EBITDA -8.95 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -38.44 0
ROE, % -40.31 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.016 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -80.91 0
Yield Ebitda, % 3.44 1
Yield EPS, % -46.19 0
Total: 1
More

Institutions Volume Share, %
Vanguard Group Inc 1392906 4.37
UBS Group AG 580578 1.82
Mission Wealth Management, LLC 501168 1.57
Laird Norton Trust Company, LLC 368835 1.16
Geode Capital Management, LLC 312472 0.98
Long Focus Capital Management, LLC 165701 0.52
Blackrock Inc. 156797 0.49
State Street Corporation 108500 0.34
Bank Of New York Mellon Corporation 96654 0.3
Susquehanna International Group, LLP 73303 0.23

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02692 17.09 1.54048
Dimensional U.S. Core Equity 2 ETF 0.00005 30.76 1.47098



Head Job title Payment Year of birth
Dr. Amit Kumar Ph.D. CEO, Chairman & Co-Chair of CBAB 1.29M 1964 (61 year)
Mr. Michael J. Catelani CPA, MBA President, COO, CFO & Corporate Secretary 788.83k 1967 (58 years)
Mr. John Roop Senior Vice President of Engineering 275k 1950 (75 years)
Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board 1955 (70 years)

Address: United States, San Jose. CA, 3150 Almaden Expressway - open in Google maps, open in Yandex maps
Website: https://www.anixa.com